Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 4,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 2 Interventional

Allopurinol Combination Study

NCT01001338
View directory record Official record
Conditions
Gout
Interventions
RDEA594, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 31, 2026, 11:36 AM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 31, 2026, 11:36 AM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 11:36 AM EDT
Recruiting Phase 4 Interventional

Study of G-CSF for DOR in Patients Undergoing IVF

NCT07871825
View directory record Official record
Conditions
Diminished Ovarian Reserve, IVF, G-CSF, Granulocyte Colony Stimulating Factor
Interventions
Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution
Drug · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
35 Years to 44 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients-1

NCT03377790
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 31, 2026, 11:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes Study of MTM in a Medicare ACO

NCT02875925
View directory record Official record
Conditions
Pain, Hypoglycemia
Interventions
MTM
Other
Lead sponsor
HealthEast Care System
Other
Eligibility
66 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 31, 2026, 11:36 AM EDT
Terminated Not applicable Interventional

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

NCT03762655
View directory record Official record
Conditions
Injury, Spinal Cord
Interventions
Neuro-Spinal Scaffold
Device
Lead sponsor
InVivo Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Sacramento, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 31, 2026, 11:36 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Fosamax in Spinal Cord Injury

NCT01131884
View directory record Official record
Conditions
Spinal Cord Injury, Osteoporosis
Interventions
Fosamax, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
View directory record Official record
Conditions
Keloid
Interventions
STP705, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT01039584
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

NCT02691247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
CLBS03 Low Dose, CLBS03 High Dose, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 31, 2026, 11:36 AM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204331
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

NCT04134715
View directory record Official record
Conditions
Healthy
Interventions
PF-06826647, Oral Contraceptive (OC)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

NCT03166215
View directory record Official record
Conditions
Developmental and/or Epileptic Encephalopathies
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 11:36 AM EDT
Recruiting Phase 4 Interventional

Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA

NCT07430085
View directory record Official record
Conditions
Periarticular Block, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Pain After Surgery, Knee Arthroplasty, Total
Interventions
bupivacaine-meloxicam (extended release), Bupivacaine, Ketorolac, Lidocaine (drug)
Combination Product · Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cranberry Township, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 1 Interventional

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TAK-875 and Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 31, 2026, 11:36 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Drug Excretion in Breast Milk

NCT06056583
View directory record Official record
Conditions
Postpartum, Lactation, Drugs in Breast Milk, Mammary Drug Transporters, BCRP, OCT1
Interventions
Cimetidine 200 MG
Drug
Lead sponsor
University of Washington
Other
Eligibility
14 Days to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

NCT03890302
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
FB704A, Placebo
Drug
Lead sponsor
Fountain Biopharma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 31, 2026, 11:36 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Oral Ketorolac for IUD Pain Reduction

NCT06853327
View directory record Official record
Conditions
IUD Insertion Pain
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hillsborough, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

Latino Semaglutide Study

NCT05087342
View directory record Official record
Conditions
Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Interventions
Semaglutide 2.4mg, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 11:36 AM EDT